HomeAI · summaries
Storia in 5 fonti
Novo Nordisk stock trades at 4-year-low on the back of disappointing Alzheimer’s trial | Fortune
The stock of the Wegovy and Ozempic maker is down nearly 50% year to date.
Confronto fonti
5 prospettive sulla stessa storiaTimeline cronologica
- ·
cnbc.com
Novo Nordisk shares plunge 10% after Alzheimer's drug trial fails to hit key target
Shares of Novo Nordisk plunged after the Danish drug pharmaceutical company said a highly-anticipated trial for Alzheimer's disease failed to meet its main goal.
- ·
cincodias.elpais.com
Novo Nordisk se desploma en Bolsa ante los malos resultados de los ensayos de uno de sus fármacos contra el Alzhéimer
La acción llega a caer un 12% hasta sus precios mínimos en más de cuatro años
- ·
forbes.com
Novo Nordisk Shares Plummet After Its Alzheimer’s Drug Trial Fails
The company said the weight loss and diabetes treatment drug failed to show any significant reduction in the progression of Alzheimer's disease in patients.
- ·
theguardian.com
Novo Nordisk shares slide after Ozempic pill fails in Alzheimer’s trials
Report dashes hopes for new use for blockbuster weight-loss drug
- ·
fortune.com
Novo Nordisk stock trades at 4-year-low on the back of disappointing Alzheimer’s trial | Fortune
The stock of the Wegovy and Ozempic maker is down nearly 50% year to date.